Webinars & Events

March 5 (Vet / LAM)

Controlled Substances 101:  How & Why You Must Comply! Parts 1, 2 & 3

Epicur and Stokes Pharmacy

 https://epicurpharma.zoom.us/webinar/register/3117720288787/WN_ndSXYEp6TUOON6lpevH4Gw#/registration 

• An Introduction to DEA Controlled Substances Regulations and Why Controlled Substances Are the Practitioner’s Biggest Risk!
• Hour 2: What Are My Controlled Substance Recordkeeping Requirements?
• How to Follow the DEA’s Regulatory Requirements

 

March 10 (NAMs)

Drug-induced liver injury assessment using adaptable liver microphysiological systems

https://www.bigmarker.com/labx-media-group/drug-induced-liver-injury-assessment-using-liver-microphysiological-systems?bmid=98ad19110398&bma=5293f268e51a&bmi=c6534f41ff46&bmid_type=member 

• Common challenges in predicting DILI across development stages
• Use of Liver MPS to unlock complex and latent DILI effects
• Application of Liver MPS for cross-species risk assessment
• Insights from comparative human and preclinical liver model studies
• Considerations for evaluating cholestatic DILI

 

March 10 (Management / Nonclinical)

Safety Digital Summit:  Actionable Steps for a Safer Lab

https://summit.labmanager.com/2026-safety/home?utm_campaign=DDN%20Webinars&utm_medium=email&_hsenc=p2ANqtz-9wwVvLg1p4P8PhYLeZgZ3TttTEz0fjCiVFSDakYWViwElmhdkVAkvdS2XE83ScjS16aAdAA_gFknUbGefuN8eoDC6BHg&_hsmi=405896436&utm_content=405896436&utm_source=hs_email

• Identify and prepare for emerging safety risks by using data and predictive tools to strengthen lab resilience.

• Evaluate new technologies—such as digital monitoring, automation, and AI—for their role in enhancing safety and compliance.

• Develop training and communication approaches that reinforce psychological safety, accountability, and long-term behavior change.

 

March 11 (Management / Nonclinical)

The Hidden Costs of In Vivo Research:  Avoiding Budget Pitfalls to Maximize Study Success

Sponsored by Charles River Laboratories

https://www.criver.com/education-training/webinar-pi-is-hidden-costs-vivo-research-avoiding-budget-pitfalls-maximize-study-success?utm_source=ismktg&utm_medium=email&utm_campaign=is-2026-q1-webinar-hidden-costs-for-in-vivo-pardot-email-1 

• How to identify and avoid common budget pitfalls in the preclinical in vivo stage
• Best practices for selecting animal models that align with your therapeutic objectives
• Why engaging model experts early and planning for animal health and genetics can prevent costly delays
• Key questions to ask during vendor evaluations to ensure operational support and facility readiness

 

March 11 (Imaging)

The Sound of Science: Mapping the Tumor Microenvironment for Advanced Therapeutic Strategies

https://insidescientific.com/webinar/the-sound-of-science-mapping-the-tumor-microenvironment-for-advanced-therapeutic-strategies/ 

This event will feature top photoacoustic thought leaders in the field.  Discover the newest possibilities in preclinical imaging with the Vevo F2 LAZR-X20 and see all the capabilities this imaging platform offers. The speakers will walk you through a demo of the system and at the end of the event, alongside VisualSonics experts, will answer all your PAI questions.

 

March 11  (NAMs)

FDA & Industry Roundtable Discussion on NAMs:  Moving Beyond Promise to Application

https://info.bioivt.com/fda-industry-virtual-nams-roundtable#register 

This virtual roundtable will feature representatives from FDA, industry and NAM development for a unique, candid conversation about what’s working, what’s missing, and what comes next for the implementation of NAMs in research and development.

 

March 11 (NAMs)

Harnessing a three-organ MPS model to assess drug and chemical safety

https://www.drugdiscoverynews.com/harnessing-a-three-organ-mps-model-to-assess-drug-and-chemical-safety-16951?utm_campaign=DDN%20Webinars&utm_medium=email&_hsenc=p2ANqtz-_X1gVggkAvwwA1aUz1YoAIt1ihlo3n1_1_Ybp_7Q6so-BqcrWCfd8am5JGlTYHBjgH7yTr6YlYlsfvRGHjHAy3Csgc9g&_hsmi=403138359&utm_content=403138359&utm_source=hs_email 

• The need for new toxicological methods, particularly for repeated dose toxicity
• Design and use of a simulated blood flow system to connect multiple organ compartments
• Determining fluid volumes and tissue mass to support multiple timepoint sampling
• Application of MPS platforms as new approach methodologies to enhance NGRA

 

Marh 17 (NCS)

Emerging Therapeutic Strategies in Oncology 

https://www.the-scientist.com/emerging-therapeutic-strategies-in-oncology-74016?utm_campaign=TS%20Webinars&utm_medium=email&_hsenc=p2ANqtz-_KddYxQ2Qgct-BHHblfQM4BzFI8JJzLXmyyQrIxnHXB36oxqVJzKYGHh9pcXg21N2EkkVWGxwmMZE5x8MizwlprsSJgQ&_hsmi=401620494&utm_content=401620494&utm_source=hs_email 

In this symposium, scientists will highlight cutting-edge cancer treatments and the translational advances guiding their development.

 

March 18 (Business Development)

Plan Ahead to Protect Your Innovation: Product Liability Risks for Medtech Startups

https://medmarc.zoom.us/webinar/register/5517707588565/WN_l_cli8A5ThyCpb7T0dRo8w#/registration

 

March 24 (Business Development / Clinical)

The Hidden Risk in Early Development:Why Programs Lose Momentum

https://www.fiercebiotech.com/premium/webinar/1376637?pk=vince-wb-032426-email-030426&utm_source=email&utm_medium=email&utm_campaign=LS-Promo-Promotions&oly_enc_id=2170I9070434G3S

• How team consistency strengthens decision quality and scalability
• The scientific and operational risk introduced by program handoffs
• Why institutional knowledge is a competitive advantage in early phase
• What true program ownership looks like beyond execution

March 24 (MPS)

From Patient Tumoroids to Scalable 3D Screening with Microfluidic Technology

https://www.thermofisher.com/us/en/home/global/forms/patient-tumoroids-scalable-3d-screening-webinar.html?cid=bid_clb_can_r01_co_pfo-1130_pgm-1522_col000000_0so_ins_op_awa_og_s00_ 

As the shift toward human‑relevant, animal‑free research and New Approach Methodologies (NAMs) accelerates, patient‑derived tumoroids are becoming essential tools in translational oncology. Join Thermo Fisher Scientific and ScreenIn3D^® to learn how standardized tumoroid culture combined with microfluidic screening helps enable scalable and reproducible 3D oncology assays.

 

March 30 (MPS)

3RsC Heart MPS Webinar 

Day 1:  https://events.teams.microsoft.com/event/e0a0d451-3d28-44c9-a7ca-b9cdb3790adf@81a2e9ee-8eaf-4532-92a2-15eca7120774

Day 2:  https://events.teams.microsoft.com/event/75fa49d6-711f-4905-827f-3cfda6f50834@81a2e9ee-8eaf-4532-92a2-15eca7120774

This virtual symposium will consist of a series of short, 15-minute, data driven presentations overviewing each company's commercially available MPS platforms followed by a panel Q&A.   

Cardiotoxicity is a majory critical adverse event finding in pharmaceutical development.  MPS cardiac models offer great potential in de-risking cardiotoxicity.

 

March 30 (Imaging)

Development of Radiopharmaceuticals: Fundamentals, Landscape, BD Deals, CMC Challenges, Theranostic Development, and IP strategies -

 Sponsored by PBSS 

  https://www.pbss.org/eventDetails/1042 

This workshop offers a comprehensive deep dive into the rapidly evolving field of radiopharmaceuticals. The agenda spans the full development lifecycle, beginning with a high-level view of the market landscape, deal-making trends, and future directions in oncology and beyond. Expert sessions will tackle critical technical hurdles, including CMC challenges, theranostic development, and manufacturing for first-in-human trials. Attendees will also gain insights into clinical strategies, such as dose selection and PET imaging agents, alongside essential legal considerations regarding IP strategy. 

 

Marh 31 (NAMs)

Modeling neurotropic viral infections using human cerebral organoids

https://www.drugdiscoverynews.com/modeling-neurotropic-viral-infections-using-human-cerebral-organoids-16988?utm_campaign=DDN%20Webinars&utm_medium=email&_hsenc=p2ANqtz-9_DJZzfu6sP2Tns25O6xeHO57dVp9kwDdyxOnsIypabb3p1Wd7BfvAjnlkxiqxP7R4WSCSf5ZPPyOKTY1ssRvuPreXSQ&_hsmi=405358649&utm_content=405358649&utm_source=hs_email 

• Modeling early human brain development with cerebral organoids
• Effects of Zika virus on organoid growth and tissue structure
• Large-area imaging and histological analysis of 3D brain models
• Scalable workflows for studying neurotropic viral infections 

April 8 (NAMs)

Advancing Drug Discovery with Complex Human In Vitro Models  

  https://www.the-scientist.com/advancing-drug-discovery-with-complex-human-in-vitro-models-73938?utm_campaign=TS%20Webinars&utm_medium=email&_hsenc=p2ANqtz-8LcVD6ek8QCpZ6CAuAw_I6hqEk2PXfuReLzG93n7LX3qeHLcHZTTDEpCChNYgH8C-6V-VaPtK3qdL5gdjtM7qwah0G3w&_hsmi=400847025&utm_content=400847025&utm_source=hs_email   

In this half-day virtual summit, a series of presentations will explore the scientific, regulatory, and operational factors impacting the use of in vitro NAMs in drug discovery.

 

April 28-29 (BD)

From Bench to Start-up

https://www.the-scientist.com/from-bench-to-startup-74023?utm_campaign=TS%20Webinars&utm_medium=email&_hsenc=p2ANqtz--305KwtUXSQ-_lKK_c5_yCGsWeMyq9_SRo0-I7_mN4jFMl_gPkwrhl2ZImxyfLlka_EatYTVe0950FJSqbCf2NU5iiwA&_hsmi=404602446&utm_content=404602446&utm_source=hs_email 

Many academic researchers generate exciting discoveries in the laboratory, but translating those insights into real-world applications often requires taking a bold step into industry. To bring their vision to life, scientists establishing biotechnology startups must navigate a journey that blends rigorous research with strategic planning, team building, and funding. In this symposium, learn how scientists turned their discoveries into startup ventures.

---------------------------------------------------------------------------------------------------------------------------------------------------------------------

Vitalizing News, Publications & Commentary